Good morning, HealthTech insiders. Eli Lilly just secured full FDA approval for an all-oral breast cancer combination built around a mutation that often emerges after endocrine therapy stops working. Inluriyo plus Verzenio more than doubled median progression-free survival in the trial's exploratory ESR1-mutated subgroup, while Guardant360 CDx gives clinicians an approved liquid-biopsy route for identifying eligible patients.
And that is only one of three very different clinical bets in today's Signal. IntraBio has won the first FDA approval for treating ataxia in patients with ataxia-telangiectasia, while Powerful Medical's Queen of Hearts moves from a headline regulatory milestone to the harder question of hospital deployment. Different diseases, different technologies, but the same pressure underneath them: healthcare wants earlier answers, clearer patient selection and fewer critical decisions made in the dark.
In today's Signal:
Lilly Wins Full Approval for Inluriyo Plus Verzenio: The oral combination is approved for ESR1-mutated advanced breast cancer after endocrine therapy, with Guardant360 CDx authorized to help identify eligible patients.
IntraBio Secures a First for Ataxia-Telangiectasia: Aqneursa becomes the first FDA-approved treatment specifically for ataxia in A-T, supported by a 73-patient randomized crossover trial.
Queen of Hearts Enters Its Deployment Test: Powerful Medical can now market its AI-ECG model in the United States, but hospitals must still prove that it improves real emergency workflows.
What We're Watching Next: Payer coverage and ESR1 testing patterns, the durability of Aqneursa's functional gains, and whether Queen of Hearts reduces delays and unnecessary escalation in routine emergency care.
In partnership with
For product teams moving at AI speed.
AI makes it easier to ship anything, even bad ideas. The hard part is knowing which ideas are worth building.
Jira Product Discovery brings your ideas, customer insights, and priorities into one place, so your team can decide what to ship and move forward with confidence.
Capture ideas, prioritize with evidence, and build living roadmaps your team can rally around—all while staying connected to delivery in Jira, so everyone can see what’s being built and why.
Better product decisions in the AI era.
LATEST DEVELOPMENTS
TARGETED ONCOLOGY & COMPANION DIAGNOSTICS
1. FDA Grants Full Approval to Eli Lilly's Inluriyo Plus Verzenio for ESR1-Mutated Breast Cancer
Promotional image from the Inluriyo media kit. Source: Eli Lilly and Company.
The FDA has fully approved Inluriyo (imlunestrant) plus Verzenio (abemaciclib) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer after at least one endocrine-therapy line.
The details:
Exploratory Subgroup Result: Among 159 patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination versus 5.5 months with imlunestrant alone.
Response and Survival Data: The hazard ratio was 0.53 (95% CI 0.35–0.80), and objective response rates were 35% versus 15%. Overall-survival data remained immature at the FDA's review.
Companion Testing: Guardant360 CDx was approved alongside the regimen to identify ESR1 mutations. The indication requires an FDA-authorized test, rather than permanently restricting eligibility to one assay.
The Signal: The approval gives an eligible subgroup another oral, post-endocrine option and strengthens the link between targeted therapy and molecular testing. That expands the opportunity for validated ESR1 testing as resistance emerges. But the headline PFS comparison came from an exploratory subgroup, so the decision should not be presented as a universal second-line standard or as making one assay an exclusive gatekeeper.
RARE DISEASE & NEUROLOGY
2. IntraBio Wins FDA Approval for Aqneursa as First Treatment for Ataxia in Ataxia-Telangiectasia
Official AQNEURSA campaign image. Source: IntraBio.
The FDA has approved Aqneursa (levacetylleucine) for ataxia in adults and children with A-T who weigh at least 15 kg, the first FDA-approved treatment specifically for ataxia in this disease.
The details:
Trial Design: The randomized, double-blind crossover study enrolled 73 adults and children. Seventy patients completed both 12-week periods, receiving Aqneursa and placebo in opposite sequences.
Measured Benefit: The trial reported a 1.88-point treatment difference on the full SARA scale. The FDA's assessment used the modified functional SARA measure and found a 0.6-point difference.
Mechanism Still Under Study: Levacetylleucine is a modified amino acid, but its proposed effects on neuronal metabolism and lysosomal-mitochondrial function should not be presented as clinically proven mechanisms.
The Signal: For an ultra-rare, heterogeneous condition, allowing patients to serve as their own controls reduced some of the noise that can overwhelm a small study. The approval shows that a controlled crossover design and disease-relevant functional endpoint can support a filing in this setting. It is not a universal regulatory shortcut; each additional indication will need its own evidence.
CARDIOVASCULAR AI & ACUTE CARE
3. FDA Grants De Novo Authorization to Powerful Medical's Queen of Hearts AI-ECG Model
The Powerful Medical team behind Queen of Hearts marks FDA De Novo authorization of its AI-ECG model for suspected urgent acute coronary syndrome. Source: Powerful Medical.
The FDA has granted De Novo authorization to PMcardio Queen of Hearts, software that flags ECG findings suggestive of urgent acute coronary syndrome (including STEMI-equivalent patterns) for clinician evaluation.
The details:
Clinical Evidence Base: Powerful Medical says the model has been evaluated in more than 40,000 patients across 20+ peer-reviewed studies, reporting roughly twofold higher sensitivity and up to fivefold fewer false positives in studied settings.
Reader-Study Performance: In a controlled study of complex STEMI-equivalent and mimic ECGs, Queen of Hearts achieved 88.9% accuracy versus 65.6% for participating emergency physicians and cardiologists.
Deployment Comes Next: The authorization follows Breakthrough Device Designation and FDA TAP participation. U.S. commercialization can begin, but hospitals still need to validate integration, governance and performance in their own patient populations.
The Signal: De Novo authorization creates a regulated device type and special controls, not an exclusive benchmark for future entrants. The next evidence will need to come from routine care: alert performance across different hospitals, effects on specialist review and cath-lab activation, and whether integration improves rather than complicates emergency workflows.
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
Oral SERD Commercial Positioning: We are watching payer coverage and oncologist prescribing across Inluriyo-based therapy and AstraZeneca's accelerated-approved camizestrant regimen, particularly how timing and reimbursement shape ESR1 testing.
European Rare-Disease Timelines: We are watching European regulatory developments for levacetylleucine in A-T and whether post-approval studies clarify the durability and clinical meaning of the measured functional gains.
Acute Care AI Protocol Integration: We are watching hospital cath-lab utilization, false-positive alerts, time to specialist review, and guideline discussions to see how Queen of Hearts performs beyond controlled studies and fits into EMS and emergency-department protocols.
💰 FOLLOW THE MONEY
The deals:
Tandem Health: $100M Series B led by the Scaleup Europe Fund, managed by EQT, to expand its AI medical assistant across Europe.
Scan.com: $220M in combined financing—$90M in Series C equity and $130M in debt, to expand its U.S. imaging network.
Graph AI: $13.3M Series A for pharmacovigilance and patient-safety workflow automation across pharma, biotech, and CRO teams.
The pattern: Capital is concentrating around regulated, operationally embedded infrastructure. Authorization can improve defensibility, but adoption still depends on distribution, measurable workflow value, and evidence that holds up beyond a pilot.
📆 UPCOMING HEALTHTECH EVENTS
Frontiers Health 2026 (Oct 20–21, 2026 | Berlin, Germany): European digital-health leaders, pharma, investors, and startups focused on innovation, commercialization, and health-system transformation.
HLTH USA 2026 (Nov 15–18, 2026 | Venetian Expo, Las Vegas, NV): Healthcare executives, founders, payers, providers, policymakers, and investors convening around care delivery, AI, policy, and investment.
RSNA 2026 (Nov 29–Dec 3, 2026 | McCormick Place, Chicago, IL): Radiology's major scientific and industry meeting, covering medical imaging, clinical research, workflow, and diagnostic AI.
🛠️ Trending HealthTech AI Tools
Guardant360 CDx: FDA-approved liquid-biopsy companion diagnostic used to identify ESR1 mutations in patients being considered for imlunestrant plus abemaciclib.
Tandem AI Medical Assistant: Multilingual ambient documentation and coding support with EHR integrations; Tandem says it has three Class IIa devices certified under the EU Medical Device Regulation.
PMcardio Queen of Hearts: FDA De Novo-authorized AI-ECG software that flags findings suggestive of urgent acute coronary syndrome for clinician review.
🛠️ Trending HealthTech AI Startups
Tandem Health (Stockholm): European clinical-AI company scaling an ambient medical assistant across 14 markets after a $100M Series B.
Graph AI (Pleasanton, California): Patient-safety software company automating pharmacovigilance workflows for life-sciences organizations after a $13.3M Series A.
Powerful Medical (New York / Bratislava): Cardiovascular AI company developing regulated ECG decision-support tools for acute-care workflows.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
The Post-Aromatase Battlefield: Breaking Down Eli Lilly's Inluriyo Strategy, Companion Diagnostics, and the Oral SERD Market Shift
How biomarker selection, testing access, and emerging oral regimens are redrawing the commercial map in endocrine-resistant breast cancer.Unlocking Orphan Neurological Indications: What IntraBio's Aqneursa Approval Says About Small-Cohort Crossover Trials
Why the trial design mattered for A-T, and why one approval should not be mistaken for a universal rare-disease precedent.How Queen of Hearts Could Reshape Emergency Triage and Cath-Lab Utilization
What the authorization changes, and what health systems still need to validate before treating AI-ECG as operational infrastructure.
Which development in today's briefing is most likely to change clinical practice first?
That's it for today!
This week's decisions point to a more demanding phase of healthcare technology adoption. Lilly has a fully approved oral combination, but its strongest reported PFS comparison comes from an exploratory ESR1-mutated subgroup. IntraBio has delivered a first for A-T, but the size and durability of the functional benefit will remain under scrutiny. Powerful Medical now has a U.S. authorization, but hospitals still need real-world workflow evidence.
The opportunity is real. So is the implementation burden. As leaders plan 2027 budgets, the winning products will be those that turn regulatory progress into measurable clinical and operational value—without asking already stretched teams to absorb another disconnected layer of technology.
Which of these developments is most likely to change your organization's care pathways first?
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal